Related Experiment Video

Updated: Jul 20, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Digoxin therapy for heart failure: an update

Spencer A Morris1, H Floyd Hatcher, Deepa K Reddy

  • 1Georgetown Hospital System, Georgetown, South Carolina 29440, USA. spenceamorris@aol.com

American Family Physician
|August 31, 2006
PubMed

Insights

Digoxin therapy for heart failure did not affect mortality but reduced hospitalizations and improved symptoms. Further research is needed to clarify optimal digoxin use, especially in women.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Digoxin is a long-standing treatment for heart failure.
  • Its precise role and optimal use in heart failure management remain subjects of ongoing investigation.

Purpose of the Study:

  • To re-evaluate the effectiveness of digoxin in heart failure treatment based on new analyses of existing trial data.
  • To investigate the impact of serum digoxin concentration and patient demographics on treatment outcomes.

Main Methods:

  • Reanalysis of data from the Digitalis Investigation Group (DIG) trial.
  • Examination of subgroup analyses focusing on serum digoxin levels and patient characteristics, including sex.

Main Results:

  • Adding digoxin to standard therapy did not alter mortality rates in heart failure patients.
  • Digoxin significantly decreased heart failure-related hospitalizations and improved patient symptoms.
  • Lower serum digoxin concentrations showed the most benefit in patients with severe heart failure.
  • Retrospective analysis suggested an increased mortality risk associated with digoxin use in women, requiring cautious interpretation.

Conclusions:

  • Digoxin may be beneficial for reducing hospitalizations and improving symptoms in heart failure, particularly at lower serum concentrations in severe cases.
  • Further prospective trials are necessary to establish optimal digoxin dosing and clarify its role in women with heart failure.
  • Digoxin is not indicated for diastolic heart failure and is not a first-line treatment for atrial fibrillation in heart failure patients.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...